157 related articles for article (PubMed ID: 3718805)
1. Debrisoquine oxidation in an Australian population.
Peart GF; Boutagy J; Shenfield GM
Br J Clin Pharmacol; 1986 May; 21(5):465-71. PubMed ID: 3718805
[TBL] [Abstract][Full Text] [Related]
2. Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population.
Xu XM; Jiang WD
Zhongguo Yao Li Xue Bao; 1990 Sep; 11(5):385-8. PubMed ID: 2130590
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
Wanwimolruk S; Patamasucon P; Lee EJ
Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
[TBL] [Abstract][Full Text] [Related]
4. N-acetylation and debrisoquine type oxidation polymorphism in Caucasians--with reference to age and sex.
Siegmund W; Hanke W; Zschiesche M; Franke G; Biebler KE; Wilke A
Int J Clin Pharmacol Ther Toxicol; 1990 Dec; 28(12):504-9. PubMed ID: 2086491
[TBL] [Abstract][Full Text] [Related]
5. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
Evans DA; Mahgoub A; Sloan TP; Idle JR; Smith RL
J Med Genet; 1980 Apr; 17(2):102-5. PubMed ID: 7381862
[TBL] [Abstract][Full Text] [Related]
6. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
Kallio J; Lindberg R; Huupponen R; Iisalo E
Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
[TBL] [Abstract][Full Text] [Related]
7. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
Peart GF; Boutagy J; Shenfield GM
Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
[TBL] [Abstract][Full Text] [Related]
8. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
Oram M; Wilson K; Burnett D; Al-Dabbagh SG; Idle JR; Smith RL
Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.
Lennard MS; Tucker GT; Woods HF; Silas JH; Iyun AO
Br J Clin Pharmacol; 1989 May; 27(5):613-6. PubMed ID: 2757883
[TBL] [Abstract][Full Text] [Related]
10. Genetically determined oxidation capacity and the disposition of debrisoquine.
Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
[TBL] [Abstract][Full Text] [Related]
11. Debrisoquine oxidation polymorphism in a Tasmanian population.
Veronese ME; McLean S
Eur J Clin Pharmacol; 1991; 40(5):529-32. PubMed ID: 1884730
[TBL] [Abstract][Full Text] [Related]
12. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
[TBL] [Abstract][Full Text] [Related]
13. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
Du YL; Lou YQ
Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
Sommers DK; Moncrieff J; Avenant J
Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
[TBL] [Abstract][Full Text] [Related]
16. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
Horai Y; Taga J; Ishizaki T; Ishikawa K
Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
[TBL] [Abstract][Full Text] [Related]
17. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
Speirs CJ; Murray S; Davies DS; Biola Mabadeje AF; Boobis AR
Br J Clin Pharmacol; 1990 Jan; 29(1):101-9. PubMed ID: 2153391
[TBL] [Abstract][Full Text] [Related]
18. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
Sloan TP; Idle JR; Smith RL
Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
[TBL] [Abstract][Full Text] [Related]
19. Interethnic dissociation between debrisoquine and desipramine hydroxylation.
Rudorfer MV; Lane EA; Potter WZ
J Clin Psychopharmacol; 1985 Apr; 5(2):89-92. PubMed ID: 3988975
[TBL] [Abstract][Full Text] [Related]
20. Debrisoquine oxidative phenotyping and psychiatric drug treatment.
Derenne F; Joanne C; Vandel S; Bertschy G; Volmat R; Bechtel P
Eur J Clin Pharmacol; 1989; 36(1):53-8. PubMed ID: 2563689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
